Taisho Pharmaceutical Holdings Co., Ltd. (4581.T) JPX

Currency In JPY

AD

Taisho Pharmaceutical Holdings Co., Ltd.

Address

3-24-1 Takada

Tokyo, 170-8655

Japan

Phone

81 3 3985 2020

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

8784

First IPO Date

December 28, 2007

Key Executives

NameTitlePayYear Born
Akira UeharaChief Executive Officer & Representative Director113M1941
Ken UeharaMD & Executive Director105MN/A
Shigeru UeharaExecutive Vice President & Director123MN/A
Jun KurodaExecutive Vice President & Director123M1958
Shinichi TanakaGeneral Manager of Corporate Communications0N/A
Tetsu WatanabeExecutive Director0N/A
AD

Description

Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.

AD